Intrathecal Immune Responses in  Stiff Person Syndrome and Multiple Sclerosis by Skorstad, Gjertrud
Intrathecal Immune Responses in  
Stiff Person Syndrome and Multiple Sclerosis 
__________________________________________________________________________________ 
 
Doctoral thesis by 
 
Gjertrud Skorstad 
 
 
 
 
 
 
 
 
Department of Neurology, Faculty Division Ullevål University Hospital 
University of Oslo, and 
Institute of Immunology, Faculty Division Rikshospitalet, University of Oslo 
2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Gjertrud Skorstad, 2010 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 947 
 
ISBN 978-82-8072-594-3 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS.  
 
Produced in co-operation with Unipub.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
3 
 
Acknowledgements
The work presented in this thesis was performed at The Department of Neurology, Ullevål University 
Hospital and The Institute of Immunology, University of Oslo in Norway during the period 2005 to 2009. I 
would like to express my gratitude for the financial support I have received from The Department of Neurology, 
Ullevål University Hospital, and I am especially indebted to Elisabeth G. Celius who believed in me and gave 
me the opportunity to explore the immunology of SPS. I will also thank the Institute of Immunology for 
providing excellent working facilities and research environment. 
First of all I would like to express my sincere gratitude to my main supervisor, Trygve Holmøy for giving 
me the opportunity to explore the interesting field of T cell immunology. His knowledge in the field of MS and 
SPS has been invaluable and motivating during these years. I have greatly appreciated his constant availability, 
and rapid feedback, particularly on written work which has been impressive. I also thank my co-supervisor 
Frode Vartdal. His immense knowledge in the field of immunology has been stimulatory to me. I am also 
grateful for your enthusiasm and optimism, and I thank him for encouraging me to work independently. I am 
also indebted to Bodvar Vandvik, a very generous person, who was always available for the great scientific 
discussion. His enthusiasm in neuroimmunology has been a constant inspiration to me.    
A special thanks goes to my dear colleague Anne Lise K. Hestvik. Her immense knowledge in MS 
immunology and oratory talent has been inspiring. Her encouragement through all these years and her constant 
belief in me has been invaluable, but most of all I have appreciated her warm friendship.   
I would like to express my sincere gratitude to my B cell collaborator, Anders Fallang. His sharing of 
excellent academic skills and enthusiasm in the field of B cell immunology has been really inspiring. I am 
deeply grateful for all the time he has spent guiding me through the work with B cells and excellent scientific 
guidance. A warm thanks goes to my dear colleague, Luka Mesin, for generously sharing his vast knowledge in 
scientific writing and for stimulating scientific discussions. I appreciate his friendship and for always being 
there through the ups and downs. Kirsti Alvik has done a fantastic job in recruiting SPS patients, a special 
thanks for her warm support and friendship during these years. Also, my warm appreciation goes to Peter 
Torjesen for helping me out with quantification and avidity analysis of GAD65 antibodies and to everyone who 
has helped me out by typing HLA.    
4 
 
Finally, I would like to thank all my great colleagues at IMMI. Thank you for all your advice, helpful and 
stimulating discussions, but most of all your friendship throughout these years.  
 
Last, a standing ovation goes to my dear family and friends. Thank you for all your patience and support 
during this “ride”. A special thank you goes to my nephew Oliver who always meets me with his wonderful 
smile each time I pick him up from school and take him to the Pannekakehuset and Dissmilis.   
 
 
Gjertrud Skorstad 
Oslo, 2009
5 
 
Table of Contents 
List of abbreviations ......................................................................................................................... 7 
Papers included in the thesis: ........................................................................................................... 9 
Papers related to the thesis: ............................................................................................................ 10 
Basic concepts in immunology ....................................................................................................... 11 
The adaptive immune response .................................................................................................. 12 
Self - tolerance mechanisms ................................................................................................... 12 
T cell immunity .......................................................................................................................... 13 
The MHC complex ................................................................................................................. 14 
The genes in the MHC complex ......................................................................................... 14 
The MHC molecules ........................................................................................................... 14 
Presentation of T cell epitopes................................................................................................ 15 
T cell activation and their effector functions .......................................................................... 16 
B cell immunity .......................................................................................................................... 17 
Immunoglobulin structure ...................................................................................................... 20 
Autoimmunity ................................................................................................................................ 21 
Immune surveillance of the central nervous system ....................................................................... 23 
Stiff Person Syndrome .................................................................................................................... 26 
Historical background ................................................................................................................ 26 
Clinical presentation ................................................................................................................... 26 
Glutamic Acid Decarboxylase .................................................................................................... 28 
GAD65 IgG antibodies and GAD65-specific T cells in SPS ................................................. 28 
Other aspects of autoimmunity in SPS ....................................................................................... 30 
Multiple Sclerosis ........................................................................................................................... 32 
Intrathecal B cell responses in MS ............................................................................................. 33 
Intrathecal humoral immune responses against microorganisms in MS ................................ 33 
Aims of the study ........................................................................................................................... 35 
Summary of the papers ................................................................................................................... 37 
Methodological considerations ....................................................................................................... 39 
Patients, sample collection and ethical considerations ............................................................... 39 
Patients ................................................................................................................................... 39 
6 
 
Sample collection ................................................................................................................... 40 
Ethical considerations ............................................................................................................. 40 
Antigens ...................................................................................................................................... 41 
Microbial antigens .................................................................................................................. 41 
GAD65 protein and GAD65 peptides ........................................................................................ 41 
Recombinant human GAD65 ................................................................................................. 41 
GAD65 peptides ..................................................................................................................... 42 
Searching for GAD65-specific T cells in SPS patients .............................................................. 43 
T cell proliferation assays and analysis of cytokine production ................................................. 45 
B cell culture .............................................................................................................................. 46 
Detection of IgG and IgG antibodies .......................................................................................... 46 
Quantification of GAD65 IgG by radioimmunoassay ............................................................ 46 
Qualitative analysis of IgG and IgG antibodies ...................................................................... 47 
Avidity and binding capacity of GAD65 IgG antibodies ....................................................... 48 
General discussion .......................................................................................................................... 50 
The relevance of CSF lymphocytes in the studies of MS and SPS ............................................ 50 
Autoimmunity to GAD65 in SPS ............................................................................................... 53 
The synthesis of GAD65 IgG antibodies ................................................................................ 53 
GAD65 as an autoantigen ....................................................................................................... 55 
Breaking tolerance to GAD65 ................................................................................................ 56 
Antibody secreting cells of the intrathecally synthesised virus-specific IgG antibodies in MS    
and GAD65 IgG antibodies in SPS ................................................................................................... 59 
Future perspectives ......................................................................................................................... 61 
Human monoclonal GAD65 IgG antibodies from SPS patients ................................................ 61 
References ...................................................................................................................................... 63 
7 
 
 
List of abbreviations 
ALCAM  activated leukocyte cell adhesion molecule 
APC  antigen presenting cell 
BAFF  B cell activating factor 
BBB  blood-brain barrier 
BCR  B cell receptor 
Bmax  binding capacity 
CIS   clinically isolated syndrome 
CCL / CXCL chemokine ligand 
CCR / CXCR chemokine receptor 
CD   cluster of differentiation 
CNS   central nervous system 
CSF  cerebrospinal fluid 
D    diversity 
DC      dendritic cell 
DMSO  dimethyl sulfoxide 
EAE  experimental autoimmune encephalomyelitis 
EBV  Epstein Barr virus  
E. coli  Escherichia coli 
GA   glatiramer acetate 
GABA  -aminobutyric acid 
GAD  glutamic acid decarboxylase 
GC   germinal centre 
HLA  human leukocyte antigen 
HSV-1  Herpes Simplex virus type-1 
ICAM / VCAM intracellular adhesion molecule / vascular cell adhesion molecule 
IEF   isoelectric focusing 
8 
 
IFN   interferon 
Ig    immunoglobulin 
IL    interleukin 
J   joining 
kDa  kilo Dalton 
MeV  Measles virus 
MHC  major histocompatibility complex 
MMP  matrix metalloproteinase 
MS   multiple sclerosis 
NLR  nucleotide oligomerisation domain-like-receptor 
NOD  non-obese diabetic 
OCBs  oligoclonal bands 
PBMC  peripheral blood mononuclear cell 
PER  progressive encephalomyelitis with rigidity 
PPH  post puncture headache  
RA   rheumatoid arthritis 
rh   recombinant human 
RIA  radioimmunoassay 
SLE  systemic lupus erythematosus  
SPS  stiff person syndrome 
T1D  type 1 diabetes 
TCR  T cell receptor 
TGF  transforming growth factor 
TH   T-helper 
TLR   Toll-like receptor 
TNF  tumour necrosis factor 
V   variable 
VGKC  voltage-gated potassium channel 
VZV  Varizella Zoster virus 
9 
 
Papers included in the thesis: 
Paper I 
Skorstad G, Vandvik B, Vartdal F and Holmøy T. MS and clinically isolated syndromes: 
Shared specificity but diverging clonal patterns of virus-specific IgG antibodies produced in 
vivo and by CSF B cells in vitro. European Journal of Neurology 2009; 16: 1124- 1129. 
 
Paper II 
Skorstad G, Hestvik AL, Torjesen P, Alvik K, Vartdal F, Vandvik B and Holmøy T. 
GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. 
European Journal of Neurology 2008; 15: 973-80. 
 
Paper III 
Skorstad G, Hestvik AL, Vartdal F and Holmøy T. Cerebrospinal fluid T cell responses 
against glutamic acid decarboxylase 65 in patients with stiff person syndrome. Journal of 
Autoimmunity 2008; 32: 24-32.  
 
 
 
 
 
 
 
10 
 
Papers related to the thesis: 
Holmøy T, Skorstad G, Røste LS, Scheie D and Alvik K. Stiff person syndrome 
associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal 
cord. Clinical Neurology and Neurosurgery 2009; 111: 708-712.  
 
Hestvik AL, Skorstad G, Price DA, Vartdal F and Holmøy T. Multiple sclerosis: 
glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Multiple 
Sclerosis 2008; 14: 749-758. 
 
 
 
 
11 
 
Basic concepts in immunology
The immune system has evolved to recognise and combat infectious agents. This is 
accomplished through the immune system’s ability to distinguish between self and non-self. 
The protection is achieved through the highly coordinated action of the innate and adaptive 
arms of the immune system (Murphy 2008).  
The innate branch of the immune system is the first line of defence against microbial 
agents. Receptors on the innate arm of the immune system are evolutionary conserved 
germline-encoded proteins which include Toll-like receptors (TLR) and nucleotide 
oligomerisation domain-like-receptors (NLR). TLRs which are receptors localised either at 
the cell surface or within endosomes, recognise a bewildering range of conserved microbial 
structures, such as bacterial cell wall components, lipoproteins, highly conserved microbial 
proteins, and bacterial and viral nucleic acids, often referred to as pathogen-associated 
molecular patterns or danger-associated molecular patterns (Janeway 2002; Kawai & Akira 
2005). By contrast, the NLRs are a family of intracellular sensors that in addition to detect 
conserved microbial structures also sense “danger signals”. These molecules alert the 
immune system upon recognition of dangerous environmental events, maybe independently 
of a microbial trigger (Fritz 2006). These relatively non-specific receptors are expressed on a 
variety of innate immune cells such as granulocytes, dendritic cells (DC), macrophages and 
natural killer cells. The innate immune system responds rapidly (within few hours) after onset 
of an infection, compared to days required for the mobilisation of the adaptive immune 
system.  
Adaptive immunity, also known as acquired immunity, is the specific response of 
lymphocytes to an antigen, including the development of immunological memory. 
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Immunological memory is known to persist for a lifetime and therefore carry the “history of 
the individual’s adaptive immune responses” (Crotty 2003; Amanna 2007). The adaptive 
immune response is generated by clonal selection and expansion of lymphocytes. The key 
players within the adaptive immunity are T cells, B cells, and professional antigen presenting 
cells (APC) including DCs, macrophages and B cells. The professional APCs are important 
in connecting the innate and the adaptive arm of the immune system by integrating innate 
information and conveying it to the T and B lymphocytes.  
 
The adaptive immune response 
Self - tolerance mechanisms 
Our immune system is the body’s sixth sense (Goodnow 2005). The mammalian immune 
system has an extraordinary capability for generating a huge receptor diversity that can 
mount a response to almost any chemical structure entering the body. The receptors that are 
involved in this “great deed” are the T cell receptors (TCR) displayed on T cells and the 
immunoglobulin (Ig) expressed on the surface of B cells as B cell receptors (BCR). Virtually 
unlimited receptor diversity can be generated in mammals by the process of variable (V), 
diversity (D), joining (J) V(D)J recombination that occur selectively in lymphocytes. During 
T- and B- cell differentiation which takes place in the central lymphoid tissues, three separate 
gene segments, the V, D and J are assembled by V(D)J recombination into unique TCR and 
BCR genes. Random addition and deletion of nucleotides at the junctions between gene 
segments further contribute to the diversity of the third hypervariable region. During the late 
phase of the immune response in the peripheral lymphoid tissues, somatic hypermutation 
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substitutes single nucleotides of BCR genes leading to the production of high-affinity 
antibodies (Goodnow 2005; Murphy 2008). 
Between 20 and 50 % of TCRs and BCRs generated by V(D)J recombination bind to self 
antigens (Zerrahn 1997; Wardemann 2003). However, the immune system has developed 
several checkpoints to prevent self-antigens from triggering self-reactive B and T 
lymphocytes. The cellular strategies engaged to deal with self-reactive receptors include: 1) 
clonal deletion; a cell bearing a “forbidden” receptor can be triggered to die according to 
Burnet’s concept of clonal selection, 2) receptor edition; further V(D)J recombination or 
somatic hypermutation of the aberrant receptor giving rise to a new receptor that is not self 
reactive, 3) “clonal anergy or tuning”; changes in gene expression can reduce the ability of 
the cell to be triggered by self-reactive receptors, and 4) extrinsic control mechanisms that 
limit the supply of essential growth factors, co-stimuli and other necessary factors including 
suppression by regulatory T cells or regulatory B cells (Burnet 1961; Kronenberg & 
Rudensky 2005; Fillatreau 2002; Hu 2007). The result of these processes is that most 
lymphocytes expressing self-reactive receptors dangerous for the host are eliminated.  
 
T cell immunity 
Progenitor T cells migrate from bone marrow to the thymus where further maturation and 
selection processes occur. Within the cortical and medullar compartments of the thymus, T 
cells undergo positive and negative selection driven by the interactions with thymic epithelial 
cells that display composites of self peptides and major histocompatibility complexes (MHC) 
molecules on their cell-surface (Starr 2003). T cells are divided into two major subsets 
identified by the expression of the unique functional cluster of differentiation (CD) surface 
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molecules, denoted CD4 and CD8. CD4+ T cells recognise peptides presented on MHC class 
II, whereas CD8+ T cells recognise peptides presented by MHC class I. 
Mature T cells leaving the thymus to enter the circulation are termed naïve. They 
circulate in the lymphatic system, through secondary lymphoid organs where they can 
interact with APCs, in principal DCs, but also macrophages and B cells. DCs which are found 
in the T cell areas of the lymphoid tissues are the most potent stimulators of T cells, and are 
believed to be the main cells that can activate naïve T cells (Banchereau & Steinman, 1998).  
 
The MHC complex 
The genes in the MHC complex 
Molecules of the MHC were first discovered for their importance in rejection of tissue 
grafts between genetically non-compatible individuals (Thorsby 2009). The MHC, named the 
human leukocyte antigen (HLA) complex in humans, is encoded by a highly polymorphic 
complex of genes contained within 4 megabase pairs (1 % of the genome) on chromosome 
6p21.3. The MHC region is divided into three; the class I gene region, followed by the class 
II and the class III gene region. Several of the genes encode classical immune response 
molecules, central in antigen presentation. The HLA genes are highly polymorphic and the 
genes are located in the class I (HLA -A, -C, -B) and class II (HLA -DR, -DQ, -DP) regions.     
 
The MHC molecules 
The function of MHC molecules is to bind peptides and display them on the cell surface 
to T cells. These membrane glycoproteins are divided into two types: Whilst MHC class I 
molecules are expressed on all nucleated cells, the MHC class II molecules are expressed 
primarily on professional APCs.  
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Whereas the MHC class I molecules are composed of  a heterodimer of a 43 kilo Dalton 
(kDa) membrane-spanning -chain bound non-covalently to a 12 kDa 2-microglobulin 
(which does not span the membrane), the MHC class II molecules are composed of two 
transmembrane non-covalently associated glycoprotein chains, the 33 kDa -chain and the 28 
kDa -chain (Murphy 2008). Whereas the MHC class I peptide-binding groove is constrained 
allowing only short peptides of 8 - 10 amino acids to bind, the ends of the MHC class II 
peptide-binding groove are open, allowing peptides of unlimited length to bind. Peptides 
eluted from MHC class II molecules are normally between 10 and 34 amino acids long 
(Murphy 2008; Madden 1995; Rudensky 1991; Vartdal 1996).  
 
Presentation of T cell epitopes 
CD8+ T cells recognise peptides derived from cytosolic proteins in the context of MHC 
class I molecules, whereas CD4+ T cells interact with MHC class II molecules that presents 
fragments of proteins that have been degraded in the endocytic and phagocytic vesicles 
(Watts 1997).  
The antigen fragments that bind to MHC class I are usually derived from endogenous 
proteins synthesised within the cell, including viral proteins, after being transported from the 
cytosol by proteins in the endoplasmatic reticulum membrane (Murphy 2008). Furthermore, 
in addition to sampling of endogenous peptides for presentation by MHC class I molecules, 
DCs and macrophages have the capability to present exogenous antigens internalised via the 
endocytic pathway to CD8+ T cells (Ackerman 2004). Such “cross-presentation” is thought to 
be critical for initiating CD8+ T cell responses to antigens that would not otherwise gain 
access to the MHC class I presentation pathway in DCs. 
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Protein antigens determined for MHC class II molecules entering the endocytic pathway 
are unfolded and degraded into peptides before reassembling as integral components of the 
mature class II complex (Jensen 1995). In the different endosomal / lysosomal compartments, 
processing of protein antigens in the MHC class II pathway is achieved by exopeptidases, 
endopeptidases, and -interferon-induced lysosomal thiol reductase, including several 
cysteine proteases. The outcome of antigen processing is thought to be a key determinant of 
the quality and quantity of a CD4+ T cell response (Watts 2004).  
 
T cell activation and their effector functions 
TCR interaction with the peptide / MHC complex is necessary, but not sufficient for 
triggering of the T cell. To become fully activated, T cells, and in particular naïve cells, must 
engage co-stimulatory molecules. The B7 molecules CD80 and CD86 displayed on the 
surface of APCs are recognised by CD28 molecules expressed by T cells. The fate of the T 
cell; death, fully activated or tolerant, depends on the strength and length of the interaction 
with peptide / MHC complex and cytokines in the environment (Lanzavecchia & Sallusto 
2001; Sallusto & Lanzavecchia 2001). Accordingly, if the T cell receives appropriate co-
stimulation, it will divide and differentiate into long-lived memory cells or effector cells. 
Triggered CD4+ effector T cells can differentiate into separate functional subsets, and 
exert their effector functions mainly through cytokine secretion. More than 20 years ago, 
Mosmann and Coffman described in mice the presence of two distinct populations of CD4+ 
T-helper (TH) cells, TH1 and TH2, characterised by their distinct cytokine profile (Mosmann 
& Coffman 1989). Studies on TH1 and TH2 cells in humans have been more challenging, 
since a high percentage of CD4+ T cells isolated from blood of healthy individuals have been 
found to display a mixed cytokine profile upon activation. Nevertheless, naïve conventional 
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CD4+ T cells have five (and possibly more) distinct fates determined by signal patterns 
received through initial interaction with the antigen. These five TH cell populations include: 
TH1 cells with interferon (IFN)- as their signature cytokine, TH2 cells producing 
predominantly the signature cytokines IL-4, IL-5, and IL-10, TH17 cells secreting IL-17, IL-
22 and transforming growth factor- (TGF-), and the recently identified skin-homing helper 
T cell subset, TH22 cells, that secrete IL-22 but neither IL-17 nor IFN-. In addition, adaptive 
regulatory T cells producing TGF- and IL-10 are responsible for suppression of other T cells 
(Zhu & Paul 2008; Duhen 2009; Trifari 2009). Notably, it was recently demonstrated that TH 
cell lineages possess an unexpected degree of plasticity, which may allow them to adopt
alternative fates or to acquire functions usually restricted to an opposite CD4+ T cell linage
(Wei 2009; Lee 2009).   
Although no such subset diversification exists among CD8+ T cells a variety of effector 
functions have been described, including cytotoxicity and cytokine production (Williams & 
Bevan 2006). Whilst some of these effector cells respond with only a limited functional 
repertoire, other can exert several effector functions such as production of IFN-, IL-2 and 
tumour necrosis factor (TNF)- (Stemberger 2007).  
 
B cell immunity 
In mammals, B cells arise from hematopoietic stem cells in the bone marrow where they 
acquire a unique BCR. B cells mature independently of antigen stimulation into pro-B cells, 
and then further into pre-B cells and immature B cells before entering the antigen-dependent 
phase in the peripheral lymphoid tissues (Browning 2006).  
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Activation of a naïve B cell is initiated in response to specific antigen binding to the 
BCR. Following antigenic stimulation, B cells can process antigen and present it on their 
MHC II molecules to antigen-specific CD4+ T cells, which give cognate help to the B cell 
(Lanzavecchia 1985). At the immunological synapse, antigen specific CD4+ T cells are 
activated and successively stimulate B cells through CD40L-CD40 interactions and cytokine 
secretion (Banchereau 1994). Optimal activation of human naïve B cells requires a third 
signal that can be delivered by TLR agonists or by cytokines produced by activated DCs 
(Ruprecht & Lanzavecchia 2006). Activated B cells can then adopt one of two fates: 1) 
movement into extrafollicular areas to become short-lived antibody producing cells, or 2) 
movement into B cell follicles and establishment of GCs (Jacob 1991). After affinity 
maturation in GCs, both long-lived memory B cells competent to give rapid and enhanced 
response to secondary antigen challenge and plasma cells capable of producing high-affinity 
antibodies are formed (Rajewsky 1996). From the GCs, long-lived plasma blasts migrate to 
the bone marrow where they differentiate into long-live plasma cells, while activated memory 
B cells may migrate to inflamed tissues and also to other organs including the brain (Knopf 
1998; Dalakas 2008).  
The TNF family members B cell activating factor (BAFF) and a proliferation-inducing 
ligand are vital factors for B cells survival, differentiation, formation of GC and production of 
Ig (Mackay & Schneider 2009). BAFF receptors are displayed on all B cells from stem cells 
to plasma cells (Dalakas 2008). High levels of BAFF are associated with the development of 
autoimmune disorders in animal models, and an excess of BAFF has been found in serum of 
patients with diverse autoimmune conditions (Mackay & Schneider 2009).   
B cells also have a role in presenting antigen to CD4+ T cells. B cells are adapted to bind 
specific soluble molecules through their cell-surface Ig and to internalise bound molecules by 
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receptor-mediated endocytosis. Since B cells constitutively express high levels of MHC class 
II molecules, high levels of specific peptide-MHC class II complexes appear on the B cell 
surface (Murphy 2008). Moreover, it has been demonstrated that receptor mediated uptake of 
antigen makes B cells 100 – 1.000 times more potent on presentation of specific antigen 
compared to other APCs, and they are therefore especially effective at presenting low 
concentrations of antigens bound by their BCR (Lanzavecchia 1990).  
Optimisation of antibody affinity is a hallmark of the humoral immune response that 
takes place in hundreds of transient microstructures called GCs. The term “GC” was coined 
more than 120 years ago by Walter Flemming, who observed accumulations of large 
lymphocytes undergoing mitosis in the follicles of lymph nodes and proposed these to be the 
major source of all lymphocytes in the body (Nieuwenhuis & Opstelten 1984). Although it is 
not Flemming’s GCs but the bone marrow which is the site of lymphocyte generation, the 
GCs are now known to be associated with T cell dependent antibody responses and are the 
most important sites for generation of high-affinity B cells. Furthermore, affinity maturation 
is often seen in parallel with an increased concentration of specific antibodies and class 
switch from IgM to other isoforms (Griffiths 1984; Siekevitz 1987; Chien 1988). Positively 
selected GC B cells may differentiate into either memory B cells or antibody-secreting 
plasma cells that subsequently exit GCs to become part of the circulating lymphocyte pool or 
migrate to the bone marrow as long-lived plasma cells, respectively (MacLennan 1994).  
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Immunoglobulin structure 
Igs are the secreted form of the BCRs. Igs are large molecules of approximately 150 kDa, 
and are composed of two different kinds of polypeptide chains: heavy chains and light chains. 
Two heavy chains are linked to each other by disulfide bonds and each light chain is linked to 
a heavy chain by disulfide bonds and noncovalent interactions. This gives rise to an antibody 
molecule with two identical antigen-binding sites. Each of the four chains has a V region at 
its amino terminus, and this region contributes to the antigen-binding site. X-ray 
crystallography of antigen : antibody complexes has demonstrated that localised regions of 
hypervariable sequences of the Ig V regions form the antigenic-binding site of the antibody. 
The carboxyl terminal region, named the constant region, comprises one of five heavy chain 
classes or isoforms (IgM, IgD, IgG, IgA and IgE), some of which are found to have several 
subtypes. The constant regions are responsible for the biological effector functions of the 
antibody (Murphy 2008). 
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Autoimmunity
Autoimmunity can be defined as adaptive immunity specific for self antigens (Murphy 
2008). An overactive autoimmune response is believed to be one possible mechanism 
underlying development of autoimmune diseases, which affect 3 - 5 % of the human 
population in the industrialised part of the world (Ashwood 2006). Autoimmune disease can 
be divided into either organ-specific disorders, such as Type 1 diabetes (T1D) and 
myasthenia gravis, or systemic illnesses, such as systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA).  
Little is known about how and why autoimmunity is triggered. A widely accepted 
hypothesis is that autoimmune diseases arise from an unfortunate combination of genetic and 
environmental factors. The low concordance rate for many autoimmune diseases among 
monozygotic twins suggests a substantial involvement of environmental factors. Evidence 
has indicated that microbes can initiate, enhance, or, conversely, abrogate autoimmunity 
(Christen 2005). Thus, a number of mechanisms for infection-induced autoimmunity have 
been postulated: 1) infection of target cells and organs, resulting in tissue destruction that 
may cause the release of sequestered antigens and enhanced antigen presentation by DCs and 
macrophages (under inflammatory conditions, upregulation of antigen processing events may 
lead to enhanced presentation of previously cryptic epitopes by the APCs which can be 
presented to self-reactive T cells), 2) epitope mimicry, and 3) bystander activation (Lehmann 
1992; Benoist & Mathis 2001).  
The involvement of activated B cells in autoimmune diseases has traditionally been viewed as a 
secondary consequence of the breakdown of T-cell tolerance (Dalakas 2008). This does not exclude 
that B cell play an instrumental role in the disease process. Thus, it was early demonstrated by 
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transfer experiments that some human diseases, such as myasthenia gravis, are directly 
mediated by pathogenic antibodies (Toyka 1975; 1977). In recent years, experimental 
evidence supporting an even more pronounced and diverse role of B cells in the pathogenesis 
of autoimmune diseases has grown: Thus, B cells could have a direct role via 1) production 
of autoantibodies or cytokine secretion, 2) indirectly influence T cell responses by presenting 
antigen or 3) by secreting antibodies that bind to antigens to form immune complexes. The 
observation that B cell depletion by using monoclonal antibodies against CD20 such as 
Rituximab, which depletes all cells of the B cell lineage except from stem cells, pro-B cells 
and plasma cells, as an effective therapy in autoimmune diseases such as RA and multiple 
sclerosis (MS), has provided an increased drive to explore the functions of B cells in 
autoimmune diseases (Edwards & Cambridge 2006; Hauser 2008).   
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Immune surveillance of the central nervous system 
The concept of immune privilege of the central nervous system (CNS) emerged from 
studies of a phenomenon that had been observed for over 130 years, namely that allografts, 
which are rapidly rejected from tissues such as skin, are accepted when placed in the brain. 
As no immune rejection was evoked, the organ was called “privileged” (Medawar 1948). 
However, more recent studies have shown a slow and inefficient clearance after inoculation 
of virus into the parenchyma of the CNS (Stevenson 2002). Consequently, the claim that the 
CNS is a site of immune privilege has been modified, and it is now rather viewed as an 
immunologically specialised site (Ransohoff 2003).  
Lymphocytes are rare in the CNS of healthy individuals partly because of the blood-brain 
barrier (BBB), which is a protective barricade that limits the entry of large molecules and 
circulating immune cells into the CNS. Immune activation is also limited in the CNS owing 
to the lack of endogenous APCs and a relative lack of lymphatic drainage of the parenchyma. 
To be able to interact with immune-competent cells in secondary lymphoid organs outside the 
BBB, the mammalian CNS has evolved pathways for delivery of antigens from the CNS 
parenchyma to the peripheral circulation. Additionally, three or more routes have been 
suggested to exist for leukocyte migration into the CNS from blood; 1) from the blood to the 
cerebrospinal fluid (CSF) via the choroid plexus within the ventricles of the CNS, 2) from the 
blood to the subarachnoid space and, 3) from the blood to the parenchymal perivascular space 
(Harling-Berg 1999; Ransohoff 2003).  
Under physiological conditions lymphocyte traffic across the BBB has been observed to 
be very low (Gowerman 2009). Pioneering studies demonstrated that the BBB strictly 
controls T cell traffic into the CNS as only activated but not resting T cells were able to 
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penetrate this barrier in healthy experimental animals (Wekerle 1987; Hicky 1991). Activated 
CD4+ memory T cells enter CNS directly from the systemic circulation to ′inspect′ the 
subarachnoid space, retaining their capability to either initiate local immune reactions or 
return to secondary lymphoid organs (Kivisakk 2003; 2009). Yet, how autoreactive T cells 
gain entry to an uninflamed brain to initiate disease has been unknown. Intriguing, it has 
recently been demonstrated that autoreactive TH17 cells expressing the chemokine receptor 
(CCR) 6 can gain access to the uninflamed CNS trough a “chink in the armour” of the BBB; 
the choroid plexus, by interaction with the chemokine ligand (CCL) 20 (Reboldi 2009; Axtell 
& Steinman 2009). CCL20 is constitutively expressed by epithelial cells of the choroid 
plexus in mice and humans, and it was suggested that the CCR6 - CCL20 axis controls an 
evolutionary conserved pathway of immune surveillance of the CNS (Reboldi 2009). 
Although huge numbers of immune cells can directly enter the CNS parenchyma through the 
“leaky” BBB during inflammation, lymphocyte recruitment into the CNS during MS or 
experimental autoimmune encephalomyelitis (EAE) is not random as T cells detected in the 
CNS parenchyma and in the CSF are phenotypically distinct from T cells found in the blood 
(Engelhardt 1998; Zeine & Owens 1992; Hestvik 2008).     
Leukocyte migration into the CNS parenchyma is a multi-step process: first, the cells 
must cross the vascular endothelial wall, and second they must transverse the astrocyte lining, 
each with its own basement membrane. The attachment of blood-borne T cells to the vascular 
bed, followed by diapedesis of immune cells across the endothelial barrier is mediated by 
several adhesion molecules, including intracellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1), 4-integrins and laminins expressed on inflamed BBB 
(Bullard 2007; Carman & Springer 2004; Engelhardt 2005). New data has shown that the 
activated leukocyte cell adhesion molecule (ALCAM) which bind to CD6 on leukocytes, 
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replaces VCAM-1 in the BBB endothelium during the development of neuroinflammatory 
diseases such as MS (Cayrol 2008). Blocking of ALCAM suppressed transmigration of T 
cells through the BBB and ameliorated EAE. Inflammatory chemokines direct leukocyte 
trafficking to inflamed tissues “on demand”; for example the chemokines CCL5 (RANTES), 
CCL3 (MIP-1), CCL4 (MIP-1) and CCL10 (IP-10) attract mainly monocytes and T cells, 
which have been associated with lesion development in MS (Farina 2005). 
To reach the brain parenchyma leukocytes must traverse the parenchymal basement 
membrane and the glial limitans. Recent evidence has shown that macrophage-derived 
gelatinase matrix metalloproteinase (MMP)-2 and MMP-9 activity is crucial for leukocyte 
penetration of the glia limitans during EAE (Agrawal 2006). Ablation of both MMP-2 and 
MMP-9 in double knockout mice confers resistance to EAE by preventing leukocyte 
infiltration into the CNS (Agrawal 2006).  
The mechanisms of B cell migration into the CNS are not well understood as those that 
apply for T cells. However, the chemokine molecules CXCL13, CXCL10 and CXCL12 that 
are secreted from the endothelial wall are up-regulated in the brain of MS patients, thereby 
facilitating the recruitment and transmigration of B cells into the brain (Ritchie 2004; Meinl 
2006). Additionally, B cell migration into the CNS is also facilitated by binding of the 
adhesion molecules very late antigen-4 and lymphocyte function-associated antigen-1 to their 
counter-receptors VCAM-1 and ICAM-1 on the endothelial cells (Alter 2003).      
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Stiff Person Syndrome
Historical background 
Stiff man syndrome was originally described in 1956 by Moersch and Woltman (Moersch 
& Woltman 1956). Their first case in 1924 was a 49-year-old male farmer from Iowa who 
was examined because of a complaint of “muscle stiffness and difficulty in walking”, hence 
the original term “stiff man syndrome”. The pioneers went on and after 32 (from 1924 to 
1956) years with seeking they published a series of 14 (10 males and 4 women) other similar 
patients (Moersch & Woltman 1956). Since then the disease has been observed more 
frequently in women than men, and is now generally referred to as Stiff Person Syndrome 
(SPS) (Goetz 1983). SPS is a rare disorder of the CNS with a reported annual incidence of 
one per million in the European population, which could be an underestimate due to 
misdiagnosis as a psychiatric disorder (Koerner 2004).  
 
Clinical presentation 
The core clinical features of classical SPS are stiffness that is prominent in axial muscles 
with co-contraction of agonist and antagonist muscles, and sudden episodic spasms in the 
absence of another disease that causes similar symptoms (Moersch & Woltman 1956; Levy 
1999). SPS usually appears in adulthood and generally has a fluctuating, slowly progressive 
course; however, in a few cases sudden death has been reported (Mitsumoto 1991). The SPS 
spectrum which include stiff limb syndrome, jerking SPS and progressive encephalomyelitis 
with rigidity (PER) share clinical, laboratory, electrodiagnostic and histopathological features 
27 
 
(Brown 1997; Leigh 1980; Whiteley 1976). Some patients present initially with stiff limb 
syndrome progress over time to classical SPS and from that to PER (Duddy & Baker 2009).   
 In 5 % of the patients, SPS is a paraneoplastic manifestation. Such patients have been 
reported to have more prominent stiffness in neck and arms than other SPS patients (De 
Camilli 1993; Butler 2000). 
Continuous co-contraction of agonist and antagonist muscles as a result of involuntary 
firing of motor units at rest is central to the pathophysiology of SPS (Lorish 1989; Thompson 
2001). Because -aminobutyric acid (GABA) is the brain’s predominant inhibitory 
neurotransmitter, GABAergic neurotransmission could play a role in the pathogenesis. 
Moreover, in vivo magnetic resonance spectroscopy has revealed a prominent and significant 
reduction in GABA levels in the motor cortex but not in the occipital cortex of SPS patients 
(Levy 2005). This is consistent with a recent paper describing changes in central GABA-A 
receptors linked benzodiazepine binding sites in selected brain regions on positron emission 
tomography scans (Perani 2007). These data strongly suggest a GABAergic deficit in SPS, 
but it remains unclear whether this is due to a functional block or reflects primarily neuronal 
loss. 
The histological findings of the few autopsies carried out so far have been inconsistent. 
The first report from Moersch and Woltman failed to demonstrate pathological lesions of 
specific areas of the CNS (Moersch & Woltman 1956). Evidence for an inflammatory process 
with selective loss of GABAergic neurons within the cerebellum and spinal cord, or a more 
aggressive inflammatory picture of perivascular lymphocytic infiltration including gliosis 
within the spinal cord, cerebral cortex, brainstem and basal ganglia have later been reported 
in some patients with SPS (Warich-Kirches 1997; Meinck 1994; Mitsumoto 1991).
Furthermore, autopsy has revealed vacuolar degeneration of anterior horn cells at the lumbar 
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segments of the spinal cord associated with prominent microglia proliferation and evidence of 
discrete infiltration of CD8+ cytotoxic T cells in patients with atypical SPS (Saiz 1999).   
 
Glutamic Acid Decarboxylase
Glutamic acid decarboxylase (GAD) converts glutamate to GABA (Erdo & Wolff 1990; 
Lernmark 1996). The two isoforms of GAD are named according to their respective 
molecular weights, GAD65 (585 amino acid residues) and GAD67 (594 amino acid residues). 
The isoforms are encoded by two different genes localised on chromosome 10 and 2 
respectively (Brilliant 1990; Karlsen 1991; Bu & Tobin 1994; Erlander 1991). Although the 
two isoforms display a high similarity in their amino acid sequences, differences are found in 
their interaction with the co-factor pyridoxal-5-phosphate and in enzyme kinetics for GABA 
production (Battaglioli 2003). Whereas cytosolic GAD67 is found to be constitutively active 
and is responsible for basal levels of GABA, the inducible cytosolic GAD65 associated with 
the GABA vesicle membrane is mostly present without its co-factor as an autoinactivated 
apoenzyme (Fenalti 2007). Upon reactivation with its co-factor, apo-GAD65 becomes holo-
GAD65 that can catalyze synthesis of GABA when additional neurotransmitter is needed 
(Kash 1997). Whilst both GAD isoforms are found in the brain, only GAD65 is found in 
pancreas, though its function there is not clear (Lernmark 1996). 
 
GAD65 IgG antibodies and GAD65-specific T cells in SPS 
GAD IgG antibodies were first reported in 1988 by Solimena and co-workers in a patient 
affected by SPS and epilepsy. The GAD65 isoform was identified as the predominant 
autoantigen (Solimena 1988; Butler 1993). Antibodies to GAD65 are also found in 80 % of 
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patients with T1D and in some patients with cerebellar ataxia, epilepsy, myoclonus, Batten 
disease and Grave’s disease (Baekkeskov 1990; Saiz 1997). While antibodies against GAD65 
in T1D target mainly conformational epitopes, the GAD65 IgG antibodies in SPS have been 
shown to be of significantly higher levels and to detect both linear and conformational 
epitopes (Kim 1994; Bjork 1994; Daw 1996). The observation that disease severity in SPS 
did not correlate with GAD65 IgG antibody levels in serum or CSF in SPS patients suggested 
that GAD65 IgG antibodies may not have a direct pathogenic role in SPS (Rakocevic 2004; 
Burns 2005). Also, GAD65 IgG antibodies do not seem to transfer the disease symptoms 
from mother to infants (Nemni 2004). As GAD65 is a cytoplasmic molecule the pathogenic 
role of GAD65 IgG antibodies has been questioned. However, intrathecal administration of 
IgG from sera of patients with GAD65 IgG antibody-associated SPS induced 
neurophysiological and biochemical SPS-correlates in rats (Manto 2007). This phenomenon 
was not observed after administration of IgG antibodies from T1D patients, which indicate 
that SPS could be the direct consequence of antibody-mediated neuronal dysfunction (Manto 
2007). Also, electrophysiological studies have shown that CSF or serum positive for GAD65 
IgG antibodies from SPS patients, and not from T1D patients, can reversibly inhibit 
GABAergic transmission in rat cerebellar slices (Dinkel 1998; Ishida 1999; Vianello 2008). 
Additional evidence for B cell involvement in SPS has been demonstrated by the 
beneficial effects of intravenous Ig (Vasconcelos 2003). It has also been observed that some 
SPS patients respond to treatment with immunomodulatory agents (Vicari 1989; Brashear & 
Phillips 1991; Hao 1999; Dalakas 2001). Plasmapheresis has been reported to be beneficial in 
some SPS patients, and in a case study the improvement of symptoms correlated with 
decreased GAD65 antibody levels (Dalakas 2009). Finally, anti-CD20 B cell therapy has 
been shown to be beneficial in reducing stiffness and increasing mobility, and resulted in 
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disappearance of GAD65 IgG antibodies in patients with PER and SPS (Saidha 2008; Baker 
2005). 
Attempts to detect GAD65-specific T cells in the peripheral blood from SPS patients have 
been few and not very successful, despite the fact that class-switched and high-affinity 
antibodies to GAD65 imply T cell involvement. Nevertheless, peripheral blood mononuclear 
cells (PBMCs) from some SPS patients have been shown to respond weakly to synthetic 
GAD65 peptides or to recombinant human (rh)GAD65 (Costa 2002; Hummel 1998; 
Lohmann 2000, 2003). Additionally, a GAD65-specific T cell line has been established from 
the blood of an SPS patient, even though no primary proliferative PBMCs response against 
GAD65 was detected in the patient (Schloot 1999).  
 
Other aspects of autoimmunity in SPS 
A striking association with other organ-specific autoimmune diseases has been described 
in SPS (Solimena 1990). T1D is relatively common in SPS and occur in approximately 30 - 
60 % of the patients, whereas the converse is not true (Solimena 1990; 1991). Other 
autoimmune diseases less commonly associated with SPS include thyroid diseases, 
pernicious anaemia, vitiligo and Graves’ disease (Solimena 1990). Furthermore, it was 
recently reported of an SPS patient with celiac disease and dermatitis herpetiformis 
(O’Sullivan 2009). In addition, antibodies against GABA receptor-associated protein, a 
protein involved in the trafficking and assembly of the GABA-A receptor has been found in 
70 % of SPS cases in one study (Raju 2006). Also, an antibody to glycine receptors has been 
identified in a patient with PER (Hutchinson 2008). In paraneoplastic variants SPS, 
antibodies are directed against two other proteins in the GABAergic and glycinergic 
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synapses; amphiphysin and gephyrin (Folli 1993; De Camilli 1993; Butler 2000). 
Interestingly, injection of serum IgG antibodies from a patient with paraneoplastic SPS and 
antibodies to amphiphysin into rats resulted in transient symptoms of stiffness with spasms 
resembling human SPS, showing that the IgG antibodies could be pathogenic (Sommer 
2005). Recent studies from the same group showed that anti-amphiphysin antibodies from the 
same patient reduced GABA-induced calcium influx in embryonic motor neurons (Geis 
2009). 
An association to HLA-DQB1*0201 and HLA-DRB1*0301 in SPS has been reported in 
two studies (Pugliese 1993; Dalakas 2000). However, it is important to note that these studies 
were carried out on relatively small populations. In a short familial report on a father and his 
daughter who both had SPS associated with GAD65 IgG antibodies, the HLA-DQB1*0201 
(father) and DRB1*0301 (daughter) alleles did not segregate with SPS (Burns 2003). 
Interestingly, HLA-DRB1*06, which is an allele that is extremely uncommon in T1D 
patients, has been reported to be associated with a lower co-occurrence of diabetes in SPS 
(Pugliese 1993).  
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Multiple Sclerosis 
MS is an inflammatory disorder of the brain and spinal cord, affecting more than 1 in 
1.000 Caucasians living in temperate climate (Pugliatti 2002). In most patients the disease 
starts with transient neurological symptoms that are denoted clinically isolated syndrome 
(CIS), whereas an MS diagnosis requires further radiological or clinical dissemination of the 
disease process (McDonald 2001). It is thought that MS occurs in individuals with complex 
genetic-risk profiles after exposure to an environmental trigger that activates auto-reactive T 
cells allowing them to migrate across the BBB. In animal models of the inflammatory aspect 
of MS, T cells reactivated by CNS-resident APCs presenting CNS antigen can then recruit 
innate immune cells, which are important actors in the demyelination and neurodegeneration 
processes (McFarland 2007; Compston 2008). The hallmark features of MS are inflammatory 
demyelinating plaques with partial axonal preservation and reactive gliosis in the brain and 
spinal cord, particularly during the early (relapsing) stage of the disease (Prineas 1984; 
Kutzelnigg 2005). Different pathways involving distinct effector mechanisms have been 
suggested to be involved in the pathogenesis, and could possibly explain differences in the 
extent of demyelination, injury of oligodendrocytes and axonal damage seen among MS 
patients (Lucchinetti 1996, 2000, 2002). However, most active lesions in patients with long-
standing MS are characterised by Igs and complement-mediated phagocytosis of 
oligodendrocytes and myelin, indicating that the pathogenesis of MS may converge to a 
common pathway (Breij 2008).  
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Intrathecal B cell responses in MS
Involvement of Igs in the pathogenesis of MS has long been suspected. Thus, intrathecal 
synthesis of gamma globulin was first described in 1942, and was shown to be at least partly 
oligoclonal in 1960 (Kabat 1942; Karcher 1960). An increase in intrathecally synthesised IgG 
antibodies which often results in oligoclonal IgG bands in the CSF is the most consistent 
clinical immunological abnormality in MS. Elevated levels of IgG antibodies in the CSF have 
been thought to be sustained by long-lived plasma cells recruited to or differentiating within 
the CNS (Prineas & Wright 1978). Extensive replacement mutations in the Ig V gene region 
of B cells and plasma cells isolated from demyelinated lesions or CSF of MS patients have 
provided evidence for an antigen-driven intrathecal humoral immune response and that 
dominant B cell clone populations can persist within the CNS (Qin 1998, 2003; Colombo 
2000, 2003; Owens 2003). Post mortem histological findings of brain tissue have revealed 
structures strikingly similar to B cell follicles containing GCs in the meninges in secondary 
progressive MS, and found that the presence of such tertiary lymphoid structures are 
associated with early onset of disease and severe cortical pathology (Prineas 1979; Serafini 
2004; Magliozzi 2007). Concordantly, a complete recapitulation of B cell differentiation 
resembling the GC reaction has been found in the CSF of MS patients (Corcione 2004).  
 
Intrathecal humoral immune responses against microorganisms in MS 
Increased IgG antibodies and oligoclonal IgG bands have been detected in the CSF of 
humans with chronic infectious CNS diseases such as subacute sclerosing panencephalitis, 
neurosyphilis, cryptococcal, varicella zoster meningoencephalitis and progressive rubella 
encephalitis (Vandvik 1973; Vartdal 1982; Porter 1977; Vartdal 1982; Coyle 1981). Studies 
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of the specificity of CSF oligoclonal IgG bands in patients with CNS infections have revealed 
that the antibodies were directed against the agent that caused the disease (Vandvik 1982; 
Vartdal 1982). Since the oligoclonal IgG bands in CNS infections are specific for the 
causative infectious agent, it is conceivable that also the persistent Ig response in MS targets 
disease-relevant antigens. Despite considerable efforts, the specificities of the main IgG 
antibody fractions appearing as oligoclonal IgG bands in the CSF of MS patients remains 
enigmatic. 
A peculiar characteristic of MS is the perpetual intrathecal synthesis of virus-specific 
antibodies (Vartdal 1982). Intrathecal synthesis of specific antibodies against one or more 
common viruses, such as measles virus (MeV), rubella virus, and varizella zoster virus 
(VZV) are found in more than 90 % of MS patients (Vartdal 1980; Sindic 1984). Most MS 
patients display oligoclonal virus-specific IgG bands restricted to the IgG1 subclass upon 
CSF analysis using IEF with immunoblot (Vartdal & Vandvik 1983). Intrathecal antibody 
syntheses against MeV and rubella virus are also present in vaccinated individuals with MS 
(Robinson-Agramonte 2007). Some of these antibodies are directed against RNA-viruses 
most unlikely to persist within the CNS, suggesting that the virus-specific antibodies are not 
part of an ongoing response against a latent infection.  
The virus-specific IgG antibodies do not correspond to the main oligoclonal IgG bands in 
the CSF and constitute approximately only 2 % of the total CSF IgG (Reiber 1998). Whereas 
CSF IgG antibodies from patients with viral encephalitis have been shown to display high 
binding affinity against the causative agent, intrathecally synthesised virus-specific IgG 
antibodies from MS patients are of low affinity (Luxton 1995).
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Aims of the study
The problems addressed in this study are all related to the dysregulated intrathecal 
immunity in two chronic neurological disorders, and are grouped under the following 
subheadings: 1) Virus-specific IgG antibodies produced in vitro by CSF B cells from patients 
with MS and CIS, 2) GAD65-specific IgG antibodies in SPS and 3) GAD65-specific T cells 
in SPS.  
  
Paper 1: Virus-specific IgG antibodies produced by CSF B cells  
in vitro from MS and CIS patients 
Although CSF B cells have been shown to produce virus-specific antibodies in vitro 
(Henriksson 1986; Salmi 1989; Baig 1989), the clonal patterns of these B cells are not 
known. In this study we wanted to explore: 
a) The clonal patterns of total IgG and of virus-specific IgG antibodies against MeV, 
VZV and herpes simplex virus type-1 (HSV-1) in supernatants of in vitro cultures of 
PBMCs and CSF cells and in sera and CSF from MS and CIS patients.  
b) The effect of BAFF on total IgG and on virus-specific IgG production in in vitro CSF 
cultures.  
 
Paper 2: GAD65-specific IgG antibodies in SPS 
Earlier studies have shown a persistent intrathecal production of IgG antibodies against 
GAD65 in SPS (Dalakas 2001; Rakocevic 2004). In this study we wanted to further 
characterise of GAD65 IgG antibodies in CSF and serum by:   
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a) Mapping the clonal patterns and subclass distribution of GAD65 IgG antibodies in 
CSF and serum.  
b) Analysing the avidities and binding capacities of serum and CSF derived GAD65 IgG 
antibodies.    
c) Investigating the temporal persistence of clonal patterns of GAD65 IgG in serum and 
CSF.   
 
Paper 3: GAD65-specific T cells from patients with SPS 
Most patients with SPS display systemic and intrathecal production of IgG antibodies 
against GAD65, but little is known about the mechanisms driving this immune response. In 
order to explore the intrathecal cellular immune response against GAD65 and compare it with 
the systemic response, we attempted to clone GAD65-specific T cells from CSF and blood 
from SPS patients and investigate whether: 
a) GAD65-sepcific T cells are present in the CSF and the blood of patients with SPS, 
and if such T cells are sequestered in the CSF?    
b) And if so, what are the HLA restriction and the cytokine profile of GAD65-specific T 
cells?  
c) Also, can we identify the GAD65 epitopes recognised by CSF and blood T cells?  
 
37 
 
Summary of the papers 
Paper 1: 
In this paper we showed that in vitro cultured CSF cells from all six MS / CIS patients 
studied, whereas only one of the four control patients, produced oligoclonal IgG. In contrast, 
in vitro production of oligoclonal IgG by PBMCs was not detected in any patient. By using 
isoelectric focusing (IEF) with immunoblot, in vitro cultured CSF cells from all six patients 
with MS / CIS were shown to produce oligoclonal IgG antibodies against either MeV, VZV 
or HSV-1. In each patient, the in vitro and in vivo intrathecally produced antibodies were 
specific for the same viruses. However, the in vitro synthesised total IgG and virus-specific 
IgG antibodies were shown to display different clonal patterns from those produced 
intrathecally in vivo. Addition of BAFF did not affect the amounts or clonal patterns of either 
total IgG or virus-specific IgG antibodies produced by in vitro CSF cells cultures.  
 
Paper 2: 
In this article, the avidities and clonal patterns of the GAD65 IgG antibodies in five 
patients with SPS were studied. By using radioimmunoassay (RIA) analyses we demonstrated 
that four of five SPS patients displayed intrathecal synthesis of GAD65 IgG antibodies. 
Intrathecally and systemically produced oligoclonal GAD65 IgG antibodies, mainly of the 
IgG1 subclass, was found in all five SPS patients by using IEF with immunoblot. The binding 
avidity of GAD65 IgG antibodies from CSF was more than 10 times higher than in GAD65 
IgG antibodies from serum in two of the patients, but did not differ significantly in the 
remaining three. All patients displayed higher GAD65 IgG antibody binding capacities 
(Bmax) in serum than in CSF. The oligoclonal GAD65 IgG bands in CSF and serum 
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persisted for years. These data indicate that a population of potentially pathogenic intrathecal 
and systemic GAD6-specific B cells or plasma cells persists in the intrathecal compartment in 
SPS patients.  
 
Paper 3: 
This is the first study of GAD65-specific T cells from the CSF of SPS patients. 11 
GAD65-specific T cells were cloned from CSF from three out of four SPS patients. In 
contrast, only one GAD65-specific T cell clone was generated from blood from one of the 
patients. The GAD65-specific T cells isolated were predominately restricted by HLA-DR. 
However, two T cell clones isolated from CSF of one of the patients studied displayed HLA-
DP restriction. Mapping of GAD65 T cell epitopes showed that CSF T cell clones recognised 
four different GAD65 epitopes that were unique to each patient. In two patients, T cells 
recognising the same GAD65 epitope in the context of identical HLA molecules were cloned 
from more than one aliquot of the same CSF sample, suggesting that these T cells belonged 
to the same or to closely related clones, and that they had been clonally expanded in vivo. The 
T cell clone derived from blood recognised a unique GAD65 epitope which differed from the 
epitopes recognised by the CSF T cells. Notably, cysteine in amino acid position 474 was 
critical for recognition of GAD65 (474-484) by the HLA-DP restricted CSF T cells isolated 
from one of the SPS patients. All GAD65-specific T cell clones displayed a predominant Th1 
phenotype, but some clones also produced Th2 cytokines. These results suggest that clonally 
expanded GAD65-specific T cells exist intrathecally in patients with SPS. 
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Methodological considerations
Patients, sample collection and ethical considerations 
Patients
In paper I, MS, CIS and control patients were recruited to the study during routine 
diagnostic examination at the Department of Neurology, Oslo University Hospital Ullevål by 
neurologists working there. 
In paper II and III, SPS patients were recruited from the Departments of Neurology at 
Oslo University Hospital Ullevål and Rikshospitalet. The latter serves as referral hospital for 
rare neurological disorders in Norway. Even though SPS is a rare disease with an estimated 
prevalence of 1 per 1.000.000, we managed to recruit five and four patients with SPS to the 
studies comprising paper II and III, respectively. Requests to other neurological departments 
in Norway have not identified additional patients with SPS and GAD65 IgG antibodies. The 
SPS patients studied therefore probable represent almost the entire Norwegian population of 
patients diagnosed with SPS. 
In paper II, control patients with neurological diseases were recruited during routine 
diagnostic workup at the Department of Neurology at Oslo University Hospital Ullevål. In 
addition, sera from T1D patients with high levels of GAD65 IgG antibodies served as 
additional controls. These were made available from the biobank at the Hormone Laboratory 
at Aker University Hospital. 
A limitation of paper III is the lack of controls. It would be beneficial to test if it was 
possible to generate GAD65-specific T cells from CSF or blood of control patients. This was 
not performed because CSF sampling and repeated blood sampling impose a substantial 
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burden on the patients, and patients not having SPS would likely be less eager to participate 
or more easily withdraw from the study.  
 
Sample collection 
In order to avoid confounding imposed by changes in the lymphocyte repertoire, paired 
blood and CSF samples were always collected within less than one hour and cultured in 
parallel. No visible contamination of blood was recorded during the spinal tap. Nevertheless, 
the first 2 ml of CSF was always discharged, as even diminutive amounts of blood would 
render the CSF sample non-representative primarily due to the high levels of cells in blood. 
To obtain detectable IgG quantities by in vitro cultures of CSF B cells, only MS, CIS and 
control patients with CSF cell counts  10 cells per l were included in paper I. In order to be 
able to generate several T cell lines from each SPS patient, GAD65-reactive T cell lines were 
generated from approximately 26 ml CSF (paper III).  
 
Ethical considerations 
All work included in this thesis has been approved by the Committee for Research Ethics 
and all other relevant institutions, and written informed consent was obtained from all 
patients before they entered the study.  
It has been reported in a previous study that post puncture headache (PPH) is common 
and occur in 46 % of females and in 21 % of males (Vilming 2001). PPH was considered the 
major torment of using CSF in this study. It has been reported that PPH is more prevalent 
with the use of a 20- compared with a 22-gauge needle (Vilming 2001). Thin needles were 
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therefore used throughout. SPS patients were recruited for the study via experienced 
neurologists who stayed in contact with the patients during the study period. 
 
Antigens
Microbial antigens 
As > 90 % of all MS patients has local synthesis against MeV and / or VZV, accordingly 
these viruses were chosen as antigens (Vartdal 1980). HSV-1 was included as 1 / 3 of MS 
patients have local production against this virus (Vartdal 1980).  
The MeV and VZV antigens were produced from tissue culture of human cells infected 
with the viruses, whereas HSV-1 antigen was produced from permanent simian kidney tissue 
culture infected with HSV-1. The lyophilised virus antigens were dissolved in distilled water, 
sonicated and stored at -70°C. The advantage of using crude cell extracts for coating is that 
these antigen preparations contain a high range of antigenic determinants (Vartdal 1980). A 
possible disadvantage could be that they also contain contaminants from the cells and growth 
medium. However, no cross-reactivity was observed between virus-specific oligoclonal IgG 
bands from the same patients (paper I). Furthermore, Borrelia burgdorferi strain 152 was 
cultured in our laboratory. 
 
GAD65 protein and GAD65 peptides 
Recombinant human GAD65 
To analyse the clonal patterns of GAD65 IgG antibodies and select for GAD65-specific T 
cells from blood and CSF, rhGAD65 was used as antigen. This antigen was expressed in 
baculovirus infected Spdoptera frugiperda cells and the purity was tested to be   95 % on 
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sodium dodecyl sulphate polyacrylamide gel electrophoresis (according to the manufacturer), 
and as well confirmed by high-performance liquid chromatography in our laboratory. As T 
cells are capable of responding to very low concentrations of antigens, even minute 
contamination may be sufficient to trigger proliferation of T cells that are specific for the 
contaminant (paper III). To confirm the specificity of GAD65-reactive T cells, a rhHLA-DQ2 
protein was included as a negative control protein (paper III). This negative control protein 
was produced in the same expression system as rhGAD65 and should therefore contain the 
same contaminations. 
 
GAD65 peptides 
To identify T cell epitopes and to further confirm the specificity of GAD6- reactive T cell 
clones, a panel of 144 16-mer overlapping peptides (approximately 50 % pure) spanning the 
complete amino acid sequence of GAD65 protein was synthesised. Each peptide overlapped 
the consecutive peptide with 12 amino residues, thereby allowing most potential CD4+ T cell 
epitopes to be represented in the panel. The solubility of the lyophilised peptides was 
variable, and the peptides were therefore initially dissolved in 100 % dimethyl sulfoxide 
(DMSO). Still, some of peptides tended to aggregate after dilution in the culture medium. 
DMSO is toxic. However; the concentration of DMSO in cell culture medium was always 
kept below the toxic concentration (0.1 %). For confirmation of specificity and determination 
of minimum epitopes, purified GAD65 peptides, including peptides that were truncated and 
contained amino acid substitutions, were purchased from another manufacturer (91-100 % 
pure).  
The peptide yield was measured in four control peptides, which were synthesised in 
addition to the 144 peptides GAD65 peptides comprising the peptide panel. The yield of the 
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GAD65 peptides was estimated from the yield of the four control peptides. To ensure that the 
concentration of each peptide was sufficient during screening experiments, a high and an 
intermediate estimated peptide concentration (100 μM and 10 μM) was used for this purpose. 
Yet, we cannot exclude that some of the peptide could be present in toxic concentrations or 
that some peptides were more or less insoluble and therefore present in too low 
concentrations to be detected by the T cells. 
 
Searching for GAD65-specific T cells in SPS patients 
GAD65-reactive T cell lines from CSF and blood were cultured in parallel following 
identical procedures to minimise the differences imposed by in vitro manipulations. In order 
to select and expand GAD65-specific T cells, T cells from CSF and blood were stimulated 
with irradiated autologous PBMCs that had been preincubated with rhGAD65 overnight. To 
select for CD4+ T cells that responded to primary antigen stimulation, IL-2 was not added 
until day seven of cell culture. Furthermore, as activated T cells express high affinity IL-2 
receptors, addition of IL-2 at day seven would provide an extra proliferation signal to 
GAD65-specific T cells that had received antigen stimulation at day one. The cells were 
further stimulated at day 16 with irradiated autologous PBMCs that had been preincubated 
with rhGAD65 overnight. The advantage of repeated antigen stimulation is that specific T 
cells are selectively and efficiently propagated (Holmøy 2004). To avoid propagation of 
allospecific T cells, GAD65-specific T cells from CSF and blood cells were cultured in 10 % 
autologous serum the first 24 days. Moreover, antigen responsive T cell lines were cloned by 
limiting dilution by seeding 0.1 - 3.0 cells per well. The cloning frequency was 1 - 20 %, 
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which makes it more than 95% likely that each T cell clone is monoclonal (Fitch & Gajewski 
1997).        
The main obstacle to the study of CSF cells is, in addition to the before mentioned 
discomfort for the patients, the limited number of cells that can be obtained from each 
patient. It is therefore hardly possible to study primary T cell responses in CSF, and the T 
cells had to be subjected to in vitro expansion. An important consideration that must be taken 
into account is that the in vitro milieu may have altered the cytokine profile of the T cells or 
favoured the expansion of particular subsets of T cells. Although cytokines known to select 
for particular subsets of CD4+ T cells were not used in the cell protocol, and although we 
were able to expand both TH1 and TH1 / TH2 polarised GAD65-specific T cell clones from 
SPS patients, it cannot be excluded that the method used to clone and expand the GAD65-
specific T cells may have influenced their cytokine profile. A further challenge is therefore to 
establish whether the GAD65-specific T cells also produce TH1 and TH1 / TH2 phenotype in
vivo. Moreover, we have been able to establish both TH1 and TH2 polarised glatiramer acetate 
(GA)-reactive CD4+ T cell lines and clones from both blood and CSF from MS patients by 
using the same protocol, and also demonstrated that TH2 polarized GA-reactive T cells 
accumulate in the CSF (Hestvik 2008). Furthermore, by using a similar method, 
Mycobactrium avium subspecies paratuberculosis-reactive CD4+ T cells with a TH1 and a TH1 
/ TH17 phenotype have been cloned from intestinal biopsies of Crohn’s disease patients 
(Olsen 2009). Collectively, these data indicate that the in vitro procedure used to clone CD4+ 
T cells in paper III is well suited for propagation of different phenotypes of CD4+ T cells.  
Irradiated autologous PBMCs were used as APCs in all T cell assays. As repeated antigen 
stimulation was used to establish GAD65-reactive T cell lines, it is particularly important to 
consider whether such APCs also stimulate naïve T cells, that are likely less relevant for the 
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disease process. PBMCs contains several potential APCs, including monocytes, B cells and 
some DCs. Notably, a previous study revealed that while both naïve and memory T cells 
from both patients with primary biliary cirrhosis and healthy subjects proliferated upon 
stimulation with antigen-loaded autologous PBMCs, whilst only memory T cells from the 
primary biliary cirrhosis patients responded to antigen-loaded costimulation-incompetent 
APCs (Shimoda 2008). It is therefore possible that the cell culture procedure applied in this 
work also propagated some naïve GAD65-specific T cells. This is, however, most relevant 
for the blood-derived T cell lines, as predominantly activated T cells are supposed to enter the 
CNS (Hickey 1991). The T cells present in CSF are therefore likely to be of an activated 
phenotype, whereas T cells with a naïve phenotype that are less relevant for the disease 
constitutes a larger proportion of the T cells present in the blood.  
 
T cell proliferation assays and analysis of cytokine production 
In this study, T cell proliferation was measured by a [3H] thymidine incorporation assay 
(paper III). This is a robust assay and well suited for screening and monitoring large number 
of T cell lines and clones. However, this method selects for T cells that proliferates upon 
activation, and neglects antigen-specific T cells with less pronounced proliferative potential, 
such as regulatory T cells. Another disadvantage of this method is the handling and disposal 
of radioisotopes, and it is therefore performed according to strict procedures.   
The cytokine secretion was measured in cell culture supernatants by employing a bead-
based multiplex system using Luminex 100 technology (paper III). Supernatants from T cells 
stimulated or not and in vitro CSF B cell cultures were harvested after 48 hours and seven 
days respectively, and kept frozen at - 70°C until analysis. In this assay, several populations 
46 
 
of beads in suspension are linked to different unique antibodies that can be separated from 
each other based on internal fluorescent dyes. The advantage of this assay is that a large 
number of samples can be analysed simultaneously for the presence of multiple cytokines.   
 
B cell culture 
To examine the clonal patterns of IgG and virus-specific IgG antibodies produced by in
vitro cultured blood and CSF cells, supernatants from short term B cell cultures were studied. 
After collection of CSF, the cells were isolated by centrifugation. To prevent cell loss, CSF 
cells were washed only once in culture medium before cultivation. The blood was obtained 
within 30 minutes of the lumbar puncture, and PBMCs and CSF cells were cultured for seven 
days before the cell-free supernatants were analysed for IgG. In pilot experiments, CSF cell 
cultures from patients with  10 cells / l did not secrete detectable amounts of IgG 
(detection limit 0.1 mg / ml) as measured with nephelometry. A short-coming of the 
nephelometry assay is that IgG concentration below 10 mg / ml is not always very reliable, 
however the measured in vitro synthesised IgG concentration correlated well with 
corresponding CSF and serum IgG when analysed on IEF for total oligoclonal IgG (paper I).       
  
Detection of IgG and IgG antibodies
Quantification of GAD65 IgG by radioimmunoassay 
To quantify GAD65 IgG in sera and CSF from SPS and control patients we have used 
RIA, which is a simple, reproducible and standardised assay that is routinely performed at the 
Hormone Laboratory at Aker University Hospital. Briefly, RIA was performed by using in
vitro transcribed and translated [3H]-Leucine labelled humane islet GAD65 (1.8 x 107 dpm / 
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pmol) performed in Escherichia coli (E. coli) (Petersen 1994). Samples were incubated 
overnight with radio labelled GAD65, followed by isolation of immunocomplexes and 
counting of [3H]-Leucine GAD65 in a Microbeta counter. In order to quantify intrathecal 
GAD65 IgG synthesis, serum IgG samples were diluted to the same total IgG concentration 
as in the corresponding CSF sample, and GAD65 IgG activity was then measured in serial 
dilutions of the CSF and adjusted serum pair. The CSF / serum GAD65 IgG ratio was 
calculated from the activity in CSF and serum at three different dilutions, corresponding to 
the most linear part of the titrations curves. 
 The main advantage of RIA is that the immunoreactions occur in free solution, meaning 
that there should be an unrestricted access for antibodies to antigenic epitopes. A potential 
disadvantage is that the in vitro translated GAD65 may not display identical antigenic 
properties as GAD65 expressed in neurons in vivo or in mammalian in vitro expression 
systems, because no posttranslational modifications take place in prokaryote cells such as E.
coli (Petersen 1994).  
 
Qualitative analysis of IgG and IgG antibodies 
The detection of intrathecal synthesis of oligoclonal IgG with IEF is a useful diagnostic 
tool both in MS and other disorders of the CNS (Deisenhammer 2006). IEF with immunoblot 
was used to examine the clonal patterns of intrathecally synthesised IgG and of virus-specific 
IgG antibodies in supernatants of in vitro cultures of PBMCs and CSF cells and in sera and 
CSF from MS and CIS patients (paper I). Additionally, this technique was employed to study 
the clonal patterns of GAD65 IgG antibodies in sera- and CSF-pairs from SPS patients and 
sera from T1D patients (paper II). IEF with immunoblot uses a pH gradient to separate IgG 
populations on the basis of their charge. The isoelectrofocused proteins were then blotted 
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onto membranes with or without antigen, and visualised with enzyme-coupled anti-IgG 
antibodies. IEF is sensitive for detection of intrathecally synthesised IgG and can be 
performed on low amounts of IgG (paper I). However, the technique is even more sensitive 
when antigen coated membranes are used to detect synthesis of oligoclonal antigen-specific 
IgG antibodies as such antibodies are not ′drowned′ by the background of total IgG 
(Deisenhammer 2006; Vartdal 1980).  
A potential drawback of this technique is that when the proteins are immobilised by 
electrostatic polarity and Van der Waals forces on the nitrocellulose membrane, steric 
hindrance may influence antibody access to antigenic epitopes (Vianello 2005). Using RIA 
and IEF with immunoblots, high GAD65 IgG antibody activity and oligoclonal bands were 
detected in sera and CSF in all patients with SPS. In contrast, high GAD65 IgG antibody 
activity was detected by RIA in sera from T1D patients, but no oligoclonal GAD65 IgG 
bands (paper II). These results may be attributed to the well described differences in target 
epitopes of GAD65 IgG antibodies between neurological and diabetes patients (Daw1996).  
 
Avidity and binding capacity of GAD65 IgG antibodies 
In our study we employed Scatchard analysis to determine the KD and Bmax of GAD65 
IgG antibodies from SPS and T1D patients (McPherson 1985). In this competition assay, 
displacement of [3H]-Leucine GAD65 binding to GAD65 IgG antibodies in serum or CSF 
samples by unlabeled GAD65 was performed by adding 0 - 15 pmol unlabeled GAD65. 
Binding data were analysed by non-linear curve analysis according to a one binding site 
model using the computer program KELL (McPherson 1985). Noteworthy, Scatchard analyses 
is not extremely reliable and the values for KD can have high margin of error (McPherson 
1985). Binding studies of antibodies can be carried out by using surface plasmon resonance 
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technique. Although binding studies of antibodies can be carried out by using surface 
plasmon resonance technique, Scatchard analysis is, however, still commonly used (Drake & 
Klakamp 2007).  
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General discussion 
The main general topics in this discussion are: 1) the relevance of CSF lymphocytes for 
the study of the immunopathogenesis of MS and SPS, 2) autoimmunity to GAD65 in SPS, 
and 3) B cell involvement in the intrathecal synthesis of virus-specific IgG antibodies in MS 
and GAD65 IgG antibodies in SPS. 
The relevance of CSF lymphocytes in the studies of MS and SPS 
 From experimental models, in particular EAE, it has become clear that immune 
responses within the CNS have specific characteristics compared with systemic immunity 
(Steinman 2001). In humans, the compartmentalisation of the immune response in CNS is 
underscored by the perpetual intrathecal synthesis of oligoclonal IgG in MS, CNS infections 
and other immune mediated neurological diseases, including SPS (Owens 2006; Dalakas 
2001). CSF T and B cells from MS patients have been reported to be clonally expanded 
(Oksenberg 1990; Wucherpfennig 1992; Qin 1998; Colombo 2000; Owens 1998, 2003; 
Obermeier 2008). As the CSF is contiguous with the extracellular fluid of the CNS, analysis 
of distribution and phenotype of inflammatory cells in the CSF may help us to understand the 
unique immunological conditions within the CNS compartment. 
 
Immune surveillance of the subarachnoid space is not necessarily identical with that of 
the CNS, and whether the IgG production from CSF cells reflects the humoral immune 
response in the CNS is unknown. In support of the relevance of CSF B cells, it has recently 
been shown that transcribed V(D)J genes from CSF B cells correspond with the amino acid 
sequence of CSF Ig (Obermeier 2008). Although the specificity of the main fractions of the 
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oligoclonal IgG is unknown, intrathecal synthesis of oligoclonal IgG antibodies against a 
broad panel of viral agents including MeV, VZV and HSV-1 is a characteristic feature of MS 
(Vartdal 1982). Comparison of the virus-specific IgG in the CSF with that produced in vitro 
by CSF B cells therefore offers a possibility to address whether CSF B cells actually reflect 
the IgG-producing B cells in the CNS. In paper I we therefore asked if the clonal patterns and 
specificities of antibodies to MeV, VZV and HSV-1 produced in vitro by CSF cells from MS 
and CIS patients correspond to that produced intrathecally in vivo. We showed that in vitro 
cultured CSF cells from these patients produced oligoclonal IgG antibodies against the same 
viruses targeted by oligoclonal CSF IgG antibodies synthesised intrathecally in vivo. 
Although the overall numbers of virus-specific IgG bands and their clonal patterns differed, 
the results indicate that the specificities of antibody producing B cells in the CSF reflect those 
of antibody synthesising cells in other locations of the CNS. 
It has been suggested that IgG-mediated complement deposition within MS lesions plays 
an important role in the pathogenesis of the disease (Breij 2008). This might suggest that the 
concentration of the most relevant antibodies is reduced in the CSF, as these antibodies may 
be bound in the MS lesions, or that the antibodies produced from CSF cells represent only a 
fraction of a much larger repertoire of antibody producing cells within the CNS. Likewise, 
the most relevant B cells might be trapped in the tissue, whereas B cells present in the CSF 
might be irrelevant bystanders. B cell clones producing low-avidity virus-specific IgG 
antibodies could possibly be an example of such irrelevant bystanders, as several of the 
viruses targeted by these IgG antibodies are not likely to be present in the CNS. Nevertheless, 
the corresponding specificities between virus antibodies in CSF and in vitro CSF B cell 
cultures highlight the relevance of studying CSF B cells in MS and possibly also in other 
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neurological diseases. The results do, however, not prove that CSF B cells correspond with B 
cells present within the CNS lesions or elsewhere in the intrathecal compartment.  
 
One of the major issues in understanding the pathophysiology of human autoimmune 
diseases is to identify the target antigens that drive the clonal expansion of autoreactive T 
cells. In paper II we showed that the synthesis of GAD65 IgG antibodies in SPS is 
oligoclonal and mediated by a stable population of affinity maturated B cell clones, 
suggesting that these antibodies are produced by B cells having received T cell help. Indeed, 
in paper III, we found evidence suggesting that HLA-DR or HLA-DP restricted GAD65-
specific CD4+ T cells accumulate in the CSF of SPS patients with intrathecal synthesis of 
GAD65 IgG antibodies. Also, in two of the patients studied, we found evidence suggesting 
that identical or closely related GAD65-specific CSF CD4+ T cell clones had been expanded 
in vivo. In contrast, only one GAD65-specific T cell clone could be raised from the blood in 
one of the patients, implying that GAD65-specific T cells from SPS patients had accumulated 
in the vicinity of the diseased organ. 
These results concur with those from other immune mediated diseases, in particular celiac 
disease, showing that disease relevant T cells accumulate in the diseased organ (Molberg 
1998). Notably even though disease-specific T cells from patients with celiac disease and 
T1D can enter the circulation for short periods of time, it has been difficult to identify 
clonally expanded disease specific-T cells in peripheral blood (Hafler 1988; Raki 2007). 
Furthermore, although a lack of a systemic response to insulin peptides in T1D patients, 
expanded T cells recognising an insulin epitope have been observed in draining pancreatic 
lymph nodes (Kent 2005). Together with the findings presented in this thesis, these 
observations support the thought that T cells present in the diseased organ more accurately 
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reflect the cell population relevant for the disease process. This question has been difficult to 
address in MS and most other immune mediated CNS diseases, because the specificity of the 
immune response is not established. In this context it is also noteworthy that a previous study 
of 36 MS patients showed an overrepresentation of CD8+ T cells expressing particular TCR-
variable  chains in the CSF compared with the blood in the majority of patients, suggesting 
that clonal T cell expansion occurring in the CSF can be detected in MS patients (Jacobsen 
2002). These results concur with the observations on GAD65-specific T cells in SPS 
presented in paper III.  
 
Autoimmunity to GAD65 in SPS 
Do GAD65 antibodies or any of the other SPS-associated autoantibodies described to date 
cause SPS, or are they only markers of autoimmunity? One well-rehearsed argument is that 
SPS autoantibodies are not pathogenic, because they are directed against intracellular proteins 
(Duddy & Baker 2009). This question is, however, beyond the scope of this thesis and will 
therefore not be further discussed. Some of the findings in this thesis may however have 
implications for the understanding of the immunobiology of GAD65 both in SPS and in more 
general terms.    
 
The synthesis of GAD65 IgG antibodies 
Even though T - B cell collaboration has not been studied directly in this thesis, the data in 
paper II and III indicating that clonally expanded GAD65-specific T cells co-exist with 
clonally expanded GAD65-specific B cells in the diseased organ, suggest a role for T cells in 
sustaining the intrathecal synthesis of GAD65 IgG antibodies in SPS. The exact anatomical 
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location for the intrathecal synthesis of GAD65 IgG antibodies in SPS remains unknown. 
Recently, one of the SPS patients studied in this thesis (patient SPS 3) has deceased. His 
symptoms included stiffness and spasms typical of SPS, as well as a malignant course with 
lower motor signs in one leg compatible with PER. This patient displayed intrathecal 
synthesis of oligoclonal GAD65 IgG antibodies as well as clonal expansion of GAD65-
specific T cells. Autopsy revealed unilateral axonal swelling, chromatolysis and vacuolisation 
of anterior horn cells of the lower spinal cord, in addition to discrete infiltration of CD8+ 
cytotoxic T cells and microglial proliferation, but no CD4+ T cells, B cells or plasma cells 
were detected within the inflamed section of the spinal cord or elsewhere in the CNS 
(Holmøy 2009). Obviously, this does not exclude that such cells were present in other 
locations of the CNS than those that were subjected to neuropathological examination. The 
meninges have to my knowledge not been examined in autopsies from SPS patients, and may 
be an important localisation for the intrathecal synthesis of GAD65 IgG. The lack of CD4+ T 
cells, B cells and plasma cells within the inflamed section of the spinal cord may imply that 
the intrathecal synthesis of GAD65 IgG antibodies is not directly related to the inflammation 
associated with tissue destruction (Holmøy 2009). Thus, GAD65-specific T - B cell 
collaboration – if it occurs – rather takes place elsewhere, either in the meninges or in other 
places inside or outside of the CNS. 
Interestingly, as shown in papers II and III, we were not able to clone GAD65-specific T 
cells from CSF from the only SPS patient (SPS 1) without substantial intrathecal synthesis of 
GAD65 IgG antibodies. Given that this patient displayed high GAD65 IgG antibody activity 
and binding capacity in serum, we speculate that physiological transfer of GAD65 IgG 
antibodies from serum to CNS may be sufficient to evoke neurological symptoms (paper II). 
Accordingly, many patients with voltage-gated potassium channel (VGKC) antibodies and 
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immunotherapy-responsive limbic encephalitis do not have oligoclonal IgG bands and their 
CSF is negative for VGKC antibodies (Vincent 2004; Jarius 2008).Thus, the lack of an 
intrathecal GAD65 IgG antibody synthesis does not necessarily exclude autoimmunity. 
 
GAD65 as an autoantigen 
An enduring question in autoimmunity is why only a limited proportion, ~ 2-3 %, of all 
human proteins becomes selected as autoantigens (Plotz 2003). It is striking that most 
autoantigens are localised intracellularly, raising the question of why they are targeted and 
the consequences of the immune response (Fenalti & Rowley 2008). The recent publication 
of N-terminally truncated crystal structures for the two isoforms, GAD65 and GAD67, have 
revealed that only the former has a very flexible and inherently mobile sequence in the C-
terminal region, which may render this region highly available to endopeptidases (Fenalti & 
Rowley 2008). Strikingly, non-obese diabetic (NOD) mice exhibit a spontaneous proliferative 
response to GAD65 at the onset of insulitis (Kaufman 1993; Tisch 1993). The T cell 
responses are initially directed towards a few so-called spontaneous epitopes (residues 509-
528 and 524-543 in the C-terminal, region of the GAD65 molecule) with later spreading to 
other T cell epitopes as the disease progresses (Kaufman 1993; Dai 2005). Interestingly, 
GAD65-specific T cell epitopes from one of the SPS patients (SPS 2) were localised within 
the C-terminal region (residues 474-484 and 555-565) of GAD65. This is in line with 
previous findings in T1D showing that T cell epitopes to GAD65 localise to residues 481-
495, 511-525 and 551-585 (Patel 1997; Nepom 2001). Furthermore, the C-terminal region is 
also targeted by CD8+ T cells and of interest, tolerance-inducing DNA coding for the C-
terminal region, GAD500-585, has been shown to protect NOD mice from diabetes (Quinn 
2001; Han 2005).  
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Furthermore by combining the N-terminally truncated high-resolution crystal structure of 
GAD65 with an “immunological” panel of 11 monoclonal antibodies to GAD65 established 
from T1D patients, the location of antibody epitopes on GAD65 has been examined (Fenalti 
2008). Two mutually exclusive clusters of B cell epitopes have been defined on opposing 
faces of the C-terminal domain of GAD65 in T1D (Fenalti 2008). Notably, T cell epitopes 
from T1D patients are localised to the same surface region of GAD65 (Fenalti & Rowley 
2008). Of interest, T and B cell epitopes from T1D patients overlap on GAD65, but the 
immunological meaning of this remains to be understood. While antibodies to GAD65 from 
T1D patients recognise mainly conformational epitopes, additional linear epitopes on GAD65 
are recognised in SPS (Lernmark 1996). Particularly, an N-terminal linear epitope that 
distinguishes sera from SPS and T1D has been repeatedly reported (Butler 1993; Kim 1994; 
Raju 2005). None of the GAD65-specific T cell epitopes from the SPS patients studied, paper 
III, overlapped with the identified linear N-terminal GAD65 antibody epitope (residues 4 - 
22). As no monoclonal antibody to GAD65 has been established from SPS patients until now, 
it cannot be excluded that the GAD65 T cell epitopes may overlap with other B cell epitopes 
to GAD65 characteristic for SPS. This question also needs to be addressed in SPS, to provide 
more insights into the GAD65 immunobiology.   
 
Breaking tolerance to GAD65 
Although a number of mechanisms have been proposed and contributing genes have been 
identified, the cause of autoimmunity is still elusive. As in most autoimmune diseases, the 
factors initiating loss of tolerance to GAD65 in SPS are not clear.   
In paper III we report two DP-restricted CSF T cell clones that initially responded weakly 
to rhGAD65 protein but later failed to respond to several batches of rhGAD65 protein. These 
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clones responded vigorously and persistently to synthetic GAD65 peptides, residues 474-484, 
showing that the failure to recognise rhGAD65 protein was not due to loss of responsiveness 
or specificity. Although we cannot exclude difference in quality between the different 
rhGAD65 protein preparations, it is peculiar that this epitope carries a cysteine residue (C474) 
found to be critical for T cell recognition. The six cysteine residues located in the N-terminal 
domain of GAD65 have been shown to form disulfide bonds in vitro (Battaglioli 2005). The 
C474 residue may be involved in a disulfide bond that is structural protected, and may 
therefore potentially be part of a cryptic epitope that has not been presented to T cells during 
T cell education in thymus. Under normal physiological conditions, cryptic epitopes are 
inefficiently processed and presented (Sercarz 1993). However, under inflammatory and 
other immunostimmulatory conditions, upregulation of antigen processing events can lead to 
enhanced processing, including enzymatic cleavage of disulfide bonds, and presentation of 
the cryptic epitopes by the APCs (Lehmann 1992). This may lead to the priming of cryptic 
epitope-specific T cells. Notably, the GAD65-specific T cells (paper III) produced substantial 
amounts of IFN-, which among other functions could induce expression of IFN- dependent 
proteases within the CNS. Moreover, further studies must be conducted to determine if 
oxidation of cysteine indeed is the cause of an inefficient processing of the GAD65 epitope. It 
is, however, an intriguing possibility that the relatively cryptic GAD65 epitope, residues 474-
484, has been unmasked by intrathecal APC during the diseases process of SPS, and therefore 
made available for intrathecal T cells.  
 
In paper II we showed that the intrathecally and systemically synthesised GAD65 IgG 
antibodies in SPS generally have high binding avidity, and that the avidity was higher in CSF 
than in serum in some patients. Yet, how the antibodies can influence antigen processing and 
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thereby affect GAD65 presentation to T cells in SPS is unknown. One possibility is that 
GAD65 IgG antibodies bind GAD65, thereby enhancing uptake and presentation of GAD65 
by APCs. Numerous studies have shown that soluble monoclonal antibodies can increase 
presentation of the antigen they bind to by facilitating antigen capture through fragment 
crystallisable receptors (Ravetch & Bolland 2001). A study using GAD65IgG antibody-
positive sera from T1D patients found enhanced presentation of an immunodominant T-cell 
epitope when GAD65 immune complexes rather than antigen alone were used to stimulate 
PBMCs (Reijonen 2000). However, it has been observed that high affinity antibodies does 
not dissociate from antigen at mildly acidic pH of the processing compartment and, therefore, 
the substrate for proteases is the antigen - antibody complex rather than antigen alone 
(Lanzavecchia 1995). In APCs antigen-antibody complexes can remain intact after 
internalisation and fragmentation by proteases along the antigen-processing pathway, thus 
protecting residues from proteolysis and thereby modulate the presentation of peptides to T 
cells (Quaratino 2005). Consequently, the fine specificity of a soluble antibody that binds to 
an antigen can affect the processing and presentation of T cell epitopes by either boosting or 
suppressing a particular epitope (Simitsek1995; Watts & Lanzavecchia 1993). Interestingly, it 
has been demonstrated in T1D that GAD65-specific B cells and antibodies can modulate the 
autoimmune T cell repertoire by down-regulating T cell epitopes in an immunodominat area 
whilst boosting distant or cryptic regions (Jaume 2002; Banga 2004). Whether the 
autoimmune GAD65-specific B cells and the antibodies they secrete may play a role in 
shaping the autoimmune T cell responses in SPS have not been elucidated. The results 
presented in paper II and III do; however, show that some of the requirements for such T-B 
cell collaboration are present in the intrathecal compartment of patients with SPS. Further 
studies are, however, required to reproduce this. Understanding how GAD65 antibodies can 
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influence presentation of T cell epitopes may hold important clues on the mechanisms 
controlling autoimmunity both in SPS and T1D.  
 
Antibody secreting cells of the intrathecally synthesised virus-
specific IgG antibodies in MS and GAD65 IgG antibodies in SPS 
The mechanisms of the perpetuating intrathecal synthesis of virus-specific IgG antibodies 
and GAD65 IgG antibodies in MS and SPS respectively, are not known. It has been shown 
that the clonal patterns of virus-specific oligoclonal IgG antibodies in MS may be dynamic 
during early stages of the disease, but that they mainly remain stable (Sandberg-Wollheim 
1987). In paper I, we showed that BAFF supplementation did not affect the amount of IgG or 
clonal patterns of virus-specific IgG antibodies produced by in vitro CSF cell cultures, 
indicating that cells producing these antibodies are of plasma cell phenotypes not affected by 
BAFF, as only transitional phases of B cells express BAFF-receptors (Dalakas 2008).  
Interestingly, it has been observed that anti-CD20 B cell depleting treatment in relapsing-
remitting MS patients significantly decreases the number of B cells in peripheral blood and 
CSF, and in addition depletes B cells from cerebral perivascular spaces, while the 
intrathecally synthesised oligoclonal IgG bands remain unaffected (Hauser 2008; Stuve 2005; 
Martin Mdel 2009; Monson 2005). This may indicate that the intrathecal synthesis of 
oligoclonal IgG antibodies in MS is generated from long-lived plasma cells not affected by 
the treatment, as CD20 is not expressed on plasma cells. The tendency of the oligoclonal IgG 
bands to persist in MS patients with anti-B cell depletion therapy may imply that the CNS 
provides a long-term survival niche for plasma cells producing antibodies that are not directly 
involved in the pathogenesis (Meinl 2006). It would be interesting to examine the persistence 
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of intrathecal virus-specific oligoclonal IgG antibodies after anti-CD20 B cell depletion to 
further understand the role of both these B cell subsets and virus-specific antibodies in MS 
pathogenesis.  
In paper II we reported that class-switched, high avidity GAD65 IgG antibodies in the 
CSF and serum from SPS patients are oligoclonal. In addition, the pattern of oligoclonal 
GAD65 IgG bands in CSF and serum in three SPS patients remained unchanged several years 
after symptom debut. Notably, these patients have not received immunomodulating drugs that 
could alter the immune response to GAD65. Of interest, a single case report on an SPS 
patient demonstrated a rapid decline of intrathecal GAD65 IgG antibodies following anti-
CD20 treatment, which suggested a successful targeting and elimination of autoantibody 
producing B cells within the CNS (Baker 2005). Furthermore, clinical trials with B cell 
depletion in other autoimmune diseases, such as RA and SLE, reported that certain 
autoantibodies, anti-DNA and rheumatoid factor, decayed after anti-CD20 B cell therapy 
(Cambridge 2003; Sfikakis 2005; Ahuja 2007). It is tempting to speculate that the 
continuously produced GAD65 IgG antibodies in SPS patients are being generated rapidly 
from renewing CD20+ B cell precursors, most consistent with the short-lived plasmablasts 
pathway. This is indeed consistent with our findings of intrathecal GAD65-specific T cells in 
paper III. Whether GAD65 specific B cells are also involved in antigen-presentation to 
GAD65-specific T cells is unknown. This may imply that the autoantibody response, 
although chronic in terms of the individual, may be a dynamic and ongoing process 
(Shlomchik 2008). 
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Future perspectives 
Human monoclonal GAD65 IgG antibodies from SPS patients 
Although the results presented in this thesis show that GAD65-specific T and B cells 
coexist intrathecally in SPS patient, their role in the pathogenesis remains unknown.  
To establish whether epitope-specific GAD65 antibodies have a role in the pathogenesis 
of SPS will require in vivo transfer studies of GAD65 antibodies from SPS patients. As 
GAD65 antibodies in CSF and serum may have different properties regarding epitope 
specificity and avidity, and because GAD65-specific antibodies only comprise a small 
fraction of IgG from serum and CSF, such experiments should ideally be performed with 
purified CSF and serum antibodies from SPS patients. Unfortunately, it is not likely to be 
feasible to obtain sufficient quantities of GAD65 antibodies from CSF of SPS patients. 
Moreover, it would not be very difficult to identify which of the many GAD65 specific IgG 
clones present in serum or CSF samples that eventually mediate the pathogenic effect. An 
alternative approach would be to use monoclonal antibodies with distinct epitope 
specificities. CSF B cells have previously been cloned from the CSF of MS patients in our 
laboratory (Holmøy 2005). Yet the limited number of antigen specific B cells has so far 
precluded the cloning of human GAD65 specific CSF B cells.  
To approach this issue, we are in the process of establishing a method for making human 
monoclonal antibodies based on an improved method for EBV immortalisation of human 
memory B cells (Traggiai 2004). The advantage of EBV-immortalised B cells is to have a 
continuous and direct source of GAD65-specific antibody secreting and antigen presenting 
cells. Additionally, B cell lines producing monoclonal GAD65 IgG offering a possibility to 
characterise monoclonal antibodies on the protein and DNA level to clarify the role of 
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epitope specificity, affinity maturation and selection of GAD65-specific IgG antibodies in 
SPS. Moreover, they could be valuable tools for the study of T - B cell collaboration in SPS. 
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